CEBPA and Myelodysplasia: All the patients reclassified into the favorable risk group had in-frame mutations in the bZIP region of CEBPα. Myelodysplasia-related gene mutations were the only reason patients were reclassified from the 2017 ELN intermediate risk group to the 2022 ELN adverse risk group.